Related Experiment Videos
Expanding indications for the use of Class III agents in patients at high risk for sudden death
1Division of Cardiology, Veterans Affairs Medical Center, Los Angeles, CA 90073, USA.
Abstract:
The evidence that antiarrhythmic compounds that act by slowing conduction velocity increase mortality in patients with cardiac disease is now compelling. Emphasis is now shifting to agents that act by lengthening repolarization and have additional antiadrenergic properties. There is preliminary evidence that pure Class III agents devoid of antisympathetic activity may also increase rather than decrease mortality in certain patients. Thus, in recent years, sotalol and amiodarone have emerged as the preferred agents for the control of most ventricular arrhythmias occurring in the setting of significant heart disease. Sotalol has not been widely studied in postinfarct patients; one trial indicated that the drug did reduce total mortality but the difference did not reach statistical significance. A number of studies with amiodarone in the postmyocardial infarction patients have revealed benefit, but these were from nonblinded studies. Two blinded, placebo-controlled studies are currently ongoing. A potential new indication of amiodarone is in patients with arrhythmias in heart failure in whom amiodarone markedly increased left ventricular ejection fraction, with a pronounced suppressant effect on premature ventricular complexes and nonsustained ventricular tachycardia and a trend for a decrease in mortality in patients with nonischemic cardiomyopathy. The most promising indication of amiodarone in low doses is in the maintenance of sinus rhythm in patients with atrial flutter and fibrillation. For the present, amiodarone appears to be the best prototype of a desirable complex antiarrhythmic compound, if its variegated side effect profile can be favorably modified from knowledge of structure-activity relationships.
Insights
New antiarrhythmic drugs focusing on repolarization, like amiodarone, are preferred for cardiac patients. While some agents show promise, careful consideration of side effects and patient populations is crucial for effective arrhythmia management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Compelling evidence suggests antiarrhythmic drugs slowing conduction increase mortality in cardiac patients.
- Emphasis is shifting towards agents lengthening repolarization with antiadrenergic properties.
Purpose of the Study:
- To review the current landscape of antiarrhythmic agents, focusing on sotalol and amiodarone.
- To evaluate the efficacy and safety of amiodarone in various cardiac conditions, including post-myocardial infarction and heart failure.
Main Methods:
- Review of existing clinical trials and studies on antiarrhythmic drug efficacy.
- Analysis of amiodarone's effects on mortality, ventricular arrhythmias, and atrial fibrillation.
Main Results:
- Sotalol showed a non-significant trend towards reduced mortality in post-infarct patients.
- Amiodarone demonstrated benefits in post-myocardial infarction patients (non-blinded studies) and showed promise in heart failure patients.
- Low-dose amiodarone is effective for maintaining sinus rhythm in atrial flutter and fibrillation.
Conclusions:
- Amiodarone is a preferred agent for ventricular arrhythmias in significant heart disease, despite side effect concerns.
- Further research into structure-activity relationships may optimize amiodarone's safety profile.
- Amiodarone shows potential in managing arrhythmias in heart failure and maintaining sinus rhythm in atrial arrhythmias.